Bureaucrats, editor, reviewer, Administrators
2,392
edits
ALLHAT: Difference between revisions
Jump to navigation
Jump to search
no edit summary
No edit summary |
No edit summary |
||
| Line 79: | Line 79: | ||
===Secondary outcomes=== | ===Secondary outcomes=== | ||
<i> All outcomes are expressed as a 6-Year Rate per 100 Persons </i> | <i> All outcomes are expressed as a 6-Year Event Rate per 100 Persons </i> | ||
* All-cause mortality: NS between all three groups | * All-cause mortality: NS between all three groups | ||
* Fatal and nonfatal stroke | * Fatal and nonfatal stroke | ||
| Line 95: | Line 95: | ||
===Subgroup analysis=== | ===Subgroup analysis=== | ||
* | * Effect by black race | ||
** Stroke: Lisinopril vs chlorthalidone (RR 1.40, 95% CI 1.17-1.68, p=0.01) | |||
** Combined CVD: Lisinopril vs chlorthalidone (RR 1.19, 95% CI 1.09-1.30, p=0.04) | |||
===Adverse events=== | ===Adverse events=== | ||
* | * Angioedema | ||
** 0.1% (chlorthalidone) vs <0.1% (amlodipine) vs 0.4% (lisinopril), p<0.001 | |||
==Criticisms== | ==Criticisms== | ||
| Line 108: | Line 111: | ||
==Funding== | ==Funding== | ||
* | * Supported by the National Heart, Lung, and Blood Institute. ALLHAT investigators received contributions of study medications supplied by Pfizer (amlodipine and doxazosin), AstraZeneca (atenolol and lisinopril) and Bristol-Myers Squibb (pravatstatin), and financial support by Pfizer. | ||
==Related articles== | ==Related articles== | ||